HZHui Zhao

Hui Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Zhao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Nian Zhou

    Department of Dermatology, Kunming Children’s Hospital (Children’s Hospital Affiliated to Kunming Medical University)

    3 shared publications
  • Zipeng Hao

    Department of Urology, Kunming Children’s Hospital (Children’s Hospital Affiliated to Kunming Medical University)

    3 shared publications
  • Bing Yan

    Department of Urology, Kunming Children’s Hospital (Children’s Hospital Affiliated to Kunming Medical University), Kunming, China

    2 shared publications
  • Chenghao Zhanghuang

    Department of Urology, Kunming Children’s Hospital (Children’s Hospital Affiliated to Kunming Medical University)

    2 shared publications
  • Jinrong Li

    Department of Urology, Kunming Children’s Hospital (Children’s Hospital Affiliated to Kunming Medical University)

    2 shared publications
  • Zhigang Yao

    Department of Urology, Kunming Children’s Hospital (Children’s Hospital Affiliated to Kunming Medical University)

    2 shared publications

Latest Publications

  • Open Access

    Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney

    by Zhigang Yao, Chenghao Zhanghuang, Nian Zhou, Jinrong Li, Zipeng Hao, Bing Yan, Hui Zhao

    Malignant rhabdoid tumor of the kidney (MRTK) is a rare and highly aggressive pediatric renal malignancy characterized by early dissemination, frequent presentation in infancy, and persistently poor survival despite multimodal therapy. Over the past decades, intensified treatment strategies combining surgery, multiagent chemotherapy, and selective radiotherapy have modestly improved outcomes, particularly in patients with localized disease. However, infants and those with stage III/IV or metastatic tumors continue to experience dismal prognosis, highlighting the limitations of further empiric escalation. The molecular hallmark of MRTK is loss of SMARCB1, a core subunit of the SWI/SNF chromatin-remodeling complex. This event provides a biologic framework for diagnosis, risk interpretation, and therapeutic development, and has shifted attention toward epigenetic and cell-cycle vulnerabilities. Early translational efforts, including EZH2 inhibition and CDK4/6 blockade, support proof of principle for biomarker-informed treatment, although renal-specific clinical evidence remains limited and single-agent activity has been modest. Immunotherapy and other emerging strategies are also being explored, but their roles in MRTK remain undefined because predictive biomarkers and disease-specific clinical datasets are lacking. In this Mini Review, we summarize the current treatment landscape of MRTK, examine why conventional multimodal therapy remains necessary but insufficient, discuss the preclinical model landscape that supports therapeutic translation, and define major priorities required to move the field toward renal-specific precision care. We argue that the next meaningful advance will depend on collaborative trials that integrate molecular profiling, faithful experimental models, rational combinations, and correlative biomarker studies from diagnosis onward.

  • miR-138-5p inhibits WiT-49 cell growth in vitro by downregulating TCF3 expression, and suppresses tumorigenesis in vivo

    by Zhigang Yao, Nian Zhou, Huangchenghao Zhang, Cuilian Li, Hongchao Jiang, Zipeng Hao, Bing Yan, Hui Zhao

    Purpose miR-138-5p plays a tumor-suppressing role, but its function in Wilms tumor (WT) has not yet been explored. This study aimed to investigate the role of miR-138-5p in the progression of WT. Methods Hematoxylin‒eosin staining was used to analyze histopathological changes in WT tissues and adjacent normal tissues. qPCR was used to detect the expression of miR-138-5p in WT tissues and cells. Immunohistochemical staining and qPCR were used to detect the expression of TCF3. The interaction between miR-138-5p and TCF3 was confirmed by correlation analysis, qPCR, and dual-luciferase assays, respectively. CCK-8, colony formation, Transwell, and wound-healing assays were performed to identify the effects of miR-138-5p and TCF3 on the proliferation and migration of WiT49 cells. A murine xenograft model was used to investigate the function of miR-138-5p on WT growth in vivo. Results miR-138-5p was expressed at low levels in WT tissues and WiT-49 cells. Functional studies demonstrated that the upregulation of miR-138-5p markedly inhibited the proliferation, colony-formation capacity, and migratory/invasive potential of WiT-49 cells. Subsequently, the therapeutic potential of miR-138-5p overexpression was confirmed in murine xenograft models, which markedly inhibited tumor growth compared with that in the control group. TCF3 is a target of miR-138-5p, and its expression is negatively correlated with that of miR-138-5p. Furthermore, the results of rescue experiments indicated that the tumor-suppressing effects of miR-138-5p in WiT-49 cells were reversed by TCF3 overexpression. Conclusions miR-138-5p could be a tumor suppressor that regulates the proliferation of WT cells by targeting and reducing TCF3 expression.

  • Open Access

    Case Report: Penile hamartoma with penile torsion in a child: etiology-targeted one-stage surgical correction and literature review

    by Zhigang Yao, Chenghao Zhanghuang, Nian Zhou, Jinrong Li, Zipeng Hao, Bing Yan, Hui Zhao

    Background: Pediatric penile hamartoma is extremely rare. Preoperative imaging often cannot definitively characterize the lesion, and histopathology remains the diagnostic gold standard. We report a child with penile hamartoma and torsion, discuss management, and compare outcomes with the literature. Methods: We retrospectively analyzed the clinical presentation, imaging, intraoperative findings, and pathology. Relevant reports were reviewed for comparison. Results: Complete excision of a ventral hamartomatous appendage plus circumcision and release of a fibrous tethering band achieved immediate torsion correction in a single stage. Histopathology showed stratified squamous epithelium with proliferative fibrous and adipose tissue containing nerve bundles, ganglion cells, and focal smooth muscle—consistent with hamartoma. Recovery was uneventful; at 12 months no recurrence was observed. Conclusion: Etiology-targeted, one-stage correction—degloving (circumcision), release of tethering bands, complete lesion excision, and simultaneous torsion repair—can be safe and effective. Long-term follow-up is advised.